Virax Biolabs Group Limited

VRAXNASDAQHealthcare● Active

$0.19

$-0.02(-9.87%)

Market Cap$817156

P/E Ratio—

52W High$1.14

52W Low$0.1

Avg Volume30.4M

Open$0.19

Beta1.24

Forecast Market Cap PE Ratio

Virax Biolabs Group Limited (VRAX) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

vrax · stock forecast · 1 analysts (3M) · FMP · updated Jun 9, 2026

Analyst Rating & Consensus

Based on 1 Wall Street analysts in the past 3 months

Buy

1 analysts

consensus

Rating Breakdown

Strong Buy

Buy

Hold

Sell

Strong Sell

Total: 1 · Buy rate: 100.0%

12-Month Price Target

High

$1.00

Consensus

$1.00

+378.9% upside

Low

$1.00

Median: $1 · Last Close: $0.21

The Virax Biolabs Group Limited (VRAX) analyst consensus is Buy, based on ratings from 1 Wall Street analysts over the past 3 months. The average 12-month VRAX price target is $1.00, representing +378.9% upside from the current price of $0.21.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Analyst price target coverage is insufficient to generate a forecast chart for this stock.

Short-Term Price Prediction

Algorithmically generated · Updated daily

Date	Predicted Price	Change	Min	Max
2026-06-10	$0.21	↑ 0.05%	$0.20	$0.21

1-day model range: $0.2–$0.21. Peak: $0.21 (+0.05%).

Long-Term Stock Price Prediction

⚠️ Long-term projections are hidden until 252 trading days of history (IPO / limited listing). Short-term tab may still show model output.

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

NEUTRAL

Based on 14 technical indicators

0%71%29%

0Buy

10Neutral

4Sell

RSI (14)46.2Neutral

MACDNEUTRAL

Refreshes daily from EOD close

Moving Averages · VRAX · Jun 9, 2026

Simple Moving Average (SMA)

MA 5$0.22SELL

MA 10$0.21SELL

MA 20$0.00NEUTRAL

MA 50$0.00NEUTRAL

MA 100$0.00NEUTRAL

MA 200$0.00NEUTRAL

Current $VRAX · Price above MA = BUY signal

Exponential Moving Average (EMA)

EMA 5$0.21SELL

EMA 10$0.23SELL

EMA 20$0.00NEUTRAL

EMA 50$0.00NEUTRAL

EMA 100$0.00NEUTRAL

EMA 200$0.00NEUTRAL

Current $VRAX · Price above MA = BUY signal

How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:

Date	Brokerage	Action	Rating
2026-01-09	HC Wainwright & Co.	Maintains	Buy→Buy

HC Wainwright & Co.2026-01-09

Maintains

Buy→Buy

Wall Street analysts have recently issued updated ratings on Virax Biolabs Group Limited (VRAX) stock. Of the recent 1 rating actions, 0 were upgrades and 0 were downgrades. 1 analysts currently cover VRAX.

Analyst Recommendation Trends

Buy ratings1 → 1

Hold ratings0 → 0

Sell ratings0 → 0

VRAX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$0M

↑ 700.0% YoY

Revenue Next Year

$1M

↑ 600.0% YoY

EPS This Year

$-3.70

EPS Next Year

$-1.90

↓ 48.6% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast VRAX EPS of $-3.70 for the current fiscal year, based on estimates from 1 analysts. The VRAX revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The VRAX stock forecast is supported by two independent data sources: analyst consensus ratings from 1 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus VRAX price target is $1.00 (+378.9% upside), with an analyst consensus of Buy.

The VRAX short-term stock prediction for tomorrow is $0.21 (+0.05%).

Virax Biolabs Group Limited trades on NASDAQ under the ticker VRAX. The VRAX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Earnings Revenue PE Ratio Financials Market Cap Insider Trades Dividends Price History

Frequently asked questions

VRAX forecast · 8 questions

According to 1 Wall Street analysts, the average 12-month VRAX price target is $1.00, with a high forecast of $1.00 and a low of $1.00. The median price target is shown in the chart above when available. This implies +378.9% potential upside from the current price of $0.21.

VRAX price targetWhat is VRAX price targetVRAX analyst price targetVRAX 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.